Related Experiment Videos
Methotrexate therapy for autoimmune hearing loss: a preliminary report
A Sismanis1, T Thompson, H E Willis
1Department of Otolaryngology-Head and Neck Surgery, Medical College of Virginia, Richmond 23298.
The Laryngoscope
|August 1, 1994
Summary
Low-dose oral methotrexate offers a potentially safer and effective treatment for autoimmune sensorineural hearing loss (SNHL). This approach showed good tolerance and minimal side effects in a small patient group.
Area of Science:
- Otolaryngology
- Immunology
- Pharmacology
Background:
- Autoimmune sensorineural hearing loss (SNHL) presents management challenges.
- Traditional treatments like steroids and cyclophosphamide carry significant adverse reactions.
- There is a need for safer, well-tolerated therapeutic options for autoimmune SNHL.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose oral methotrexate in patients with autoimmune SNHL.
- To explore methotrexate as a less toxic alternative to conventional therapies.
Main Methods:
- A small cohort of five patients with autoimmune SNHL was treated with low-dose oral methotrexate.
- Patient outcomes and adverse effects were monitored.
Main Results:
- Preliminary findings suggest methotrexate may be effective for autoimmune SNHL and related otologic symptoms.
- The treatment was well-tolerated, with minimal reported side effects.
- Methotrexate demonstrated good patient tolerance.
Conclusions:
- Low-dose oral methotrexate shows promise as a viable and safer treatment for autoimmune SNHL.
- Further research is warranted to confirm these preliminary findings and establish optimal protocols.